ARTICLE | Clinical News
SY162: Began Phase II testing
April 23, 2001 7:00 AM UTC
ThromboGenics Ltd., Dublin, Ireland Product: SY162 Business: Cardiovascular Therapeutic category: Thrombolysis/Thrombosis Target: Fibrin Description: Staphylokinase variant Indication: Treat acute pe...